MOA

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer

Retrieved on: 
Tuesday, June 6, 2023
Volunteering, Human resources, Business development, IPO, Obesity, MOA, Benjamin Arsanis, Bryant University, Diabetes, T1D, Facility, Clinical trial, Business, Babson College, PYY, Grey, Sale, Acquisition, DSM-IV codes, Patient, CBO, Overweight, CFO, Therapy, T2D, Pharmaceutical industry, Management, Vaccine, Philosopher's stone

BERKELEY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).

Key Points: 
  • BERKELEY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).
  • In addition, Gray will lead cross-functional teams that include Business Development, Human Resources, IT and Facilities.
  • Gray joins Carmot with nearly 20 years of public-private leadership experience including broad strategic, financial and operating experience in global companies.
  • I am honored to be joining Carmot, a company that is committed to transforming patients' lives through potentially differentiated therapies for metabolic diseases," stated Gray.

Pembina Pipeline Announces Agreement with Marubeni Corporation to Develop a Low Carbon Ammonia Project and Outlines Vision for Pembina Low Carbon Complex

Retrieved on: 
Tuesday, May 30, 2023
Commercial Building & Real Estate, Manufacturing, Construction & Property, Other Transport, Transport, Oil, Gas, Alternative Energy, Environment, Energy, Engineering, Sustainability, Carbon, Area studies, MOA, Alberta's Industrial Heartland, Senior, PLCC, Front-end loading, Pembina Pipeline, Hydrogen, Marubeni, Marketing, PPL, Corporate development, Methanol, Multimedia, Ammonia, Movement, NYSE, Risk, Investment, Water, Natural gas, TC Energy, Project, TSX, Growth, PBA, Facility, CO2, CCUS, Western Canada, Fort Saskatchewan

Pembina and Marubeni will utilize their complementary strengths to develop and execute the Project.

Key Points: 
  • Pembina and Marubeni will utilize their complementary strengths to develop and execute the Project.
  • The Project would potentially serve as an anchor development to advance Pembina's ongoing efforts to establish a new growth platform known as the Pembina Low Carbon Complex ("PLCC").
  • Tenants are contemplated to capture CO2 and direct those emissions to Pembina in support of the proposed Alberta Carbon Grid.
  • Commercial discussions are progressing with various potential tenants and strategic partners and Pembina looks forward to providing future updates.

Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes

Retrieved on: 
Thursday, May 25, 2023
Janus, Volunteering, Obesity, RA, MOA, Diabetes, T1D, Clinical trial, Millennium Management, LLC, PYY, Doctor of Philosophy, Patient, DSM-IV codes, Overweight, Column, Therapy, T2D, Disease, Vaccine, Medical imaging, Pharmaceutical industry, Philosopher's stone

BERKELEY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced a $150 million oversubscribed and up-sized Series E financing. The financing was led by Deep Track Capital. The syndicate also included new investors 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millennium Management, TCGX, Venrock Healthcare Capital Partners and existing investors RA Capital Management, The Column Group and Willett Advisors. The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.

Key Points: 
  • The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.
  • “With three clinical-stage candidates currently in development, this financing enables us to continue to advance clinical trials that will yield key data readouts this year and through 2024."
  • Results from the multiple ascending dose cohorts will be presented at the 83rd American Diabetes Association Scientific Sessions.
  • By making subtle improvements in molecular design, Carmot may be able to achieve clinically relevant tolerability and efficacy benefits.

Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions

Retrieved on: 
Tuesday, May 23, 2023
Volunteering, MOA, Type 2 diabetes, T1D, Weight loss, Clinical trial, PYY, Patient, DSM-IV codes, Overweight, GIP, Therapy, T2D, Live Session, Medical imaging, Birth control, Communications satellite, Philosopher's stone

BERKELEY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced multiple presentations to take place at the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA. Details regarding the poster presentations are as follows:

Key Points: 
  • Additional Phase 2 trials in overweight and obese adults are planned for 2023.
  • Carmot has recently initiated another Phase 1 MOA study in overweight and obese patients with type 1 diabetes (T1D) and expects to initiate a Phase 2 proof-of-concept clinical trial in overweight and obese patients with T1D in the second half of 2023.
  • CT-996 (oral, small molecule GLP-1 receptor agonist), which has recently initiated a Phase 1 clinical trial in overweight and obese otherwise healthy adults.
  • A long-acting peptide tyrosine-tyrosine (PYY) analogue, which is in preclinical development.

Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients

Retrieved on: 
Thursday, May 25, 2023
CD47, MOA, PD, GBM, Survival, American Society of Clinical Oncology, Glioblastoma, Trial of the century, ASCO, MDSC, PD-L1, Patient, TME, Decompression (diving), CR, CTL, CD36, Therapy, Tumor microenvironment, Phenotype, Society, SD, Pharmaceutical industry

VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).

Key Points: 
  • VT1021 is a first-in-class compound that, by binding to MDSCs, induces the expression of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME).
  • In a phase I/II clinical study in solid tumors (NCT03364400), VT1021 demonstrated promising single-agent clinical activity against recurrent glioblastoma.
  • Vigeo is already studying the therapeutic effect of VT1021 in both newly diagnosed and recurrent GBM in an ongoing phase II/III clinical study (NCT03970447).
  • Title: Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

Revolo Biotherapeutics Presents New Preclinical Data for ‘1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference

Retrieved on: 
Monday, May 22, 2023
IAV, Infection, Mouse, MOA, Eosinophilic esophagitis, TNF, Neutrophil, Allergy, Macrophage, Gastric lavage, ATS, Influenza A virus, IL-6, Inflammation, American Thoracic Society, Lung, Dexamethasone, Animal, International Conference on Emerging Infectious Diseases, Organic acid, Patient, Immune system, Viral, Viral load, Acute respiratory distress syndrome, Chemokine, Cytokine, Lymphocyte, Immunosuppression, Conference, PBS, Autoimmunity, Disease, Vaccine, Revolo

NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced new preclinical data discussed in a poster presentation at the American Thoracic Society (ATS) 2023 International Conference. The poster showcases the ability of its immune-resetting drug candidate ‘1104 to inhibit and reduce lung inflammation without immunosuppression in a new model of acute respiratory distress syndrome (ARDS) associated with influenza infection.

Key Points: 
  • The poster showcases the ability of its immune-resetting drug candidate ‘1104 to inhibit and reduce lung inflammation without immunosuppression in a new model of acute respiratory distress syndrome (ARDS) associated with influenza infection.
  • “The data continues to highlight the unique mechanism of action (MOA) of ‘1104, acting ahead of the inflammatory cascade to reset the immune system.
  • Three days after infection, animals received either PBS (negative control) or 30µg of polyinosinic-polycytidylic acid (poly I:C) to exacerbate influenza-induced lung inflammation.
  • At 48 hours after the poly I:C challenge, bronchoalveolar lavage fluid was collected to conduct differential cell counts and to measure cytokines.

Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bispecific monoclonal antibody, Monoclonal antibody, MOA, B-cell lymphoma, Therapy, CD3, CD20, Bi-specific T-cell engager, DLBCL, Roche, Cancer, Research, Antibody, Trial of the century, Patient, Location, Growth, Health Canada, Vaccine, Indication

The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Insight On Bispecific Antibodies In Clinical Trials: > 700 Bispecific Antibodies
    Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
    The introduction of antibody-based therapeutics has been a game changer in the field of cancer therapy.
  • The continued expansion in research and development of antibody biologics has brought in the era of bispecific antibodies.
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
    15.

Anima Biotech to Present at Locust Walk RNA Innovation Conference

Retrieved on: 
Monday, May 8, 2023
Partnership, MOA, University of Massachusetts, Research, RNA, Messenger, Science, Beth Israel, AI, Conference, Vaccine

BERNARDSVILLE, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of small molecule mRNA drugs and their mechanisms of action by phenotypic screening with AI driven MOA elucidation, today announced that Iris Alroy, Ph.D., chief scientific officer and co-founder of Anima, will present the company's mRNA Lightning™ platform at the upcoming Locust Walk RNA Innovation Conference.

Key Points: 
  • BERNARDSVILLE, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of small molecule mRNA drugs and their mechanisms of action by phenotypic screening with AI driven MOA elucidation, today announced that Iris Alroy, Ph.D., chief scientific officer and co-founder of Anima, will present the company's mRNA Lightning™ platform at the upcoming Locust Walk RNA Innovation Conference.
  • ET and will highlight how Anima is advancing the science of mRNA regulation through its innovative approach.
  • The Locust Walk RNA Innovation Conference is hosted in partnership with Frank Slack, Ph.D., Director of the Beth Israel RNA Medicine Initiative, and Phil Zamore, Ph.D., Director of the UMass Chan RNA Medicine Institute.
  • Locust Walk is hosting a virtual one-day investor and partner conference exploring innovations in RNA research and development, including:

Viva Biotech's Recent Conferences & Events Review

Retrieved on: 
Friday, May 5, 2023
Molecule, Dai, GMP, Communication, SAPA, Senior, ASMS, Marketing, Development, Journal, Patient, Environment, EHS, Science, Friends, Synthesis, Attention, Production, A39, CDE, Drug discovery, PCSK9, CIO, FDA, Conference, NMPA, BD, D, Medicinal chemistry, PROTAC, Intellectual property, AACR, Exhibition, SPR, Challenge, API, Parlour, American Association for Cancer Research, PDT, Biomedicine, Forum, Synthetic biology, Factorization of polynomials, Drug development, MOA, CMC, Booth, NDA, EDT, CDMO, Estate (law), Artificial intelligence, Fine chemical, Pharmaceutical industry, Medical device, Bioassay, IND

Experts shared a lot of great contents and idea in these conferences and events.

Key Points: 
  • Experts shared a lot of great contents and idea in these conferences and events.
  • As one of the key players in innovative drug discovery CRO, Viva has served thousands of global innovative drug development clients in the past decade.
  • He believes that in the future, Viva Biotech can empower more domestic innovative drug companies and help them achieve internationalization in original drug research.
  • Viva would continue to strengthen one-stop drug development and manufacturing service platform to better empower the development of biopharmaceutical innovation.